Literature DB >> 29523331

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Christine Sekaggya-Wiltshire1, Mohammed Lamorde2, Agnes N Kiragga2, Kelly E Dooley3, Moses R Kamya4, Andrew Kambugu2, Jan Fehr5, Yukari C Manabe3, Barbara Castelnuovo2.   

Abstract

Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-tuberculosis drugs; Concentrations; Treatment outcomes

Mesh：

Substances：

Year:  2017        PMID： 29523331      PMCID： PMC5846119          DOI： 10.1016/j.tube.2017.11.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


  28 in total

Review 1.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

2.  Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.

Authors:  Julie B Prahl; Isik S Johansen; Arieh S Cohen; Niels Frimodt-Møller; Åse B Andersen
Journal:  J Antimicrob Chemother       Date:  2014-06-16       Impact factor: 5.790

3.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

Review 4.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

Authors:  Jakko van Ingen; Rob E Aarnoutse; Peter R Donald; Andreas H Diacon; Rodney Dawson; Georgette Plemper van Balen; Stephen H Gillespie; Martin J Boeree
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

5.  Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.

Authors:  A Mah; H Kharrat; R Ahmed; Z Gao; E Der; E Hansen; R Long; D Kunimoto; R Cooper
Journal:  Int J Tuberc Lung Dis       Date:  2015-02       Impact factor: 2.373

6.  Peak plasma rifampicin level in tuberculosis patients with slow culture conversion.

Authors:  K-C Chang; C-C Leung; W-W Yew; K-M Kam; C-W Yip; C-H Ma; C-M Tam; E C-C Leung; W-S Law; W-M Leung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-24       Impact factor: 3.267

7.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

8.  Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Authors:  Jong Sun Park; Jae-Yeon Lee; Yeon Joo Lee; Se Joong Kim; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Junghan Song; Jae Ho Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

9.  Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Authors:  Neesha Rockwood; Jotam G Pasipanodya; Paolo Denti; Frederick Sirgel; Maia Lesosky; Tawanda Gumbo; Graeme Meintjes; Helen McIlleron; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

10.  Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.

Authors:  Ana Requena-Méndez; Geraint Davies; David Waterhouse; Alison Ardrey; Oswaldo Jave; Sonia Llanet López-Romero; Stephen A Ward; David A J Moore
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191
View more
  2 in total

1.  Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.

Authors:  Anushka Naidoo; Maxwell Chirehwa; Veron Ramsuran; Helen McIlleron; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Ravesh Singh; Sinaye Ncgapu; John Adamson; Katya Govender; Paolo Denti; Nesri Padayatchi
Journal:  Pharmacogenomics       Date:  2019-02-15       Impact factor: 2.638

2.  The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review.

Authors:  Tesemma Sileshi; Esayas Tadesse; Eyasu Makonnen; Eleni Aklillu
Journal:  Clin Pharmacol       Date:  2021-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.